GlycoMimetics (GLYC) Tops Q1 EPS by 1c

GlycoMimetics (NASDAQ: GLYC) reported Q1 EPS of ($0.33), $0.01 better than the analyst estimate of ($0.34).

“The first quarter of 2019 was one of focused activity in the clinical development arena. We continued to identify and initiate new sites and enroll participants in our Company-sponsored Phase 3 trial in relapsed or refractory AML patients. We also worked closely with our two consortia partners to expand our late-stage uproleselan program, culminating in our announcement that the NCI consortium dosed its first patient in its trial in late April. During the same period, we worked with clinical collaborators at Duke Cancer Institute to plan our next trial for GMI-1359, a dual antagonist of E-selectin and CXCR-4, and defined individuals with breast cancer and bone metastases as our initial target study population,” said Rachel King, GlycoMimetics Chief Executive Officer.

For earnings history and earnings-related data on GlycoMimetics (GLYC) click here.

You May Also Be Interested In

• Keurig Dr Pepper coffee chief to depart ahead of planned split
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Sun Communities names Ileana McAlary as general counsel and EVP